Background
Introduction
The two variables that classify and stage chronic kidney disease are impaired kidney function and increased albuminuria. Albuminuria is strongly and independently associated with risk for all-cause mortality and cardiovascular mortality, as well as with risk for renal outcomes, such as end-stage renal disease, acute kidney injury and progressive chronic kidney disease (1) (2) (3) (4) . Traditionally, albuminuria is categorized into three stages: normoalbuminuria (<30 mg/24h), microalbuminuria (30-300 mg/24h) and macroalbuminuria (>300 mg/24h). Whereas macroalbuminuria is generally accepted to indicate renal disease, microalbuminuria is often regarded to be the result of generalized endothelial damage, secondary to the presence of hypertension and/or diabetes mellitus (5, 6 ).
As such, the value of 'isolated' microalbuminuria, defined as microalbuminuria in the absence of a cardiovascular history, hypertension and diabetes, to predict adverse health-related outcomes has been questioned (7) (8) (9) . A number of recent studies suggested, however, that microalbuminuria may not only be the consequence of, but may also precede the development of, hypertension and diabetes (10) (11) (12) (13) . Whether isolated microalbuminuria is also associated with an increased risk for cardiovascular events and mortality is yet unknown.
We therefore investigated the association between isolated microalbuminuria and incident cardiovascular events and mortality in a prospective, observational cohort study, and compared it to the risk associated with microalbuminuria in the presence of a cardiovascular disease (CVD) history, hypertension or diabetes. Additionally, we studied whether isolated microalbuminuria is associated with incident hypertension and/or diabetes mellitus.
Patients and Methods

Study design and population
This study was conducted among subjects who participated in the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) study, which started in 1997. This prospective cohort study investigates the natural course of albuminuria and its relation to renal and CVD. Details of the study protocol have been published elsewhere (14, 15) .
In summary, all inhabitants of the city of Groningen aged 28-75 years were sent a questionnaire on demographics, disease history, smoking habits, use of medication and a vial to collect a first-morning-void urine sample. Of these subjects, 40 856 responded (response rate: 47.8%).
From these subjects, the PREVEND cohort was selected with the aim to create a cohort 40 enriched for the presence of high albuminuria. After exclusion of patients with type 1 diabetes mellitus (defined as requiring the use of insulin) and pregnant females (defined by self-report), all subjects with a urinary albumin concentration of >10 mg/L (7768) were invited, of which 6000 participated. Furthermore, a randomly selected control group with a urinary albumin concentration of <10 mg/L (3394) was invited, of which 2592 participated. These 8592 subjects constitute the actual PREVEND cohort and were studied in more detail. Thereafter, participants were invited to visit the outpatient clinic for a medical examination at 3-year intervals. Albuminuria was measured every screening round. Participants were instructed to collect all urine during two 24-h periods and to refrain from such collection in the case of fever or heavy exercise.
For the present study, albuminuria is given as the mean of two 24-h urinary albumin excretions (mg/24h) obtained at the baseline screening. We excluded participants without information on baseline albuminuria, diabetes, hypertension or cardiovascular history (n =104) and participants with baseline albuminuria >300 mg/24h (n =132), leaving 8356 subjects for analysis. The PREVEND study was approved by the medical ethics committee of the University Medical Center Groningen, the Netherlands, and conducted in accordance with the guidelines of the Declaration of Helsinki. All participants gave written informed consent.
Measurements
At each screening round participants filled in a questionnaire on demographics and health status, including medication use. Information on drug use was complemented with data from community pharmacies (16). Height and weight were measured. Blood pressure was measured in a supine position every minute for 10 and 8 min, respectively, with an automatic Dinamap device (Dinamap XL Model 9300; Johnson-Johnson Medical). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were calculated as the mean of the last 2 of 10 successive measurements. Concentrations of cholesterol, glucose and creatinine were measured in serum using standard methods (Kodak Ektachem autoanalyzer, Eastman Kodak, Rochester, NY, USA). Urine albumin concentration was determined in fresh urine samples by a commercial immuno-turbidimetry assay with a sensitivity of 2.3 mg/L and intra-and interassay coefficients of variation of 4.4 and 4.3%, respectively (BNII, Dade Behring Diagnostica, Marburg, Germany).
Definitions
Participants were defined as smoking when they had smoked regularly in the year before the baseline screening according to the questionnaire. Body mass index (BMI) was calculated as the ratio between weight (kg) and the square of height (m). 
Statistical analysis
To assess the association of isolated microalbuminuria with incident adverse health outcomes, we divided our study population into four subgroups according to baseline presence/absence of hypertension, diabetes or CVD, and baseline presence/absence of microalbuminuria. All statistical analyses were performed with SPSS version 18.0 software. For all analyses, a P-value of <0.05 was adopted to indicate statistical significance.
Baseline characteristics are expressed as percentages in case of categorical data. Continuous data are reported as mean and standard deviation (SD). In case of skewed distribution, the median with interquartile range (IQR) are presented. To calculate the differences in baseline characteristics between the various subgroups a χ 2 test was used for categorical data, for continuous parametric data, Student's t-test was used and a Mann-Whitney U-test for continuous nonparametric data. The risk for cardiovascular events and mortality during the follow-up was calculated using Cox regression analysis and expressed as hazard ratio (HR).
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Survival time for Cox regression analysis was defined as the period from the date of urine collection of the participant until the date of first cardiovascular event, date of death or 1
January 2009 (end of follow-up). In the case of a person moving to an unknown destination, the date on which the person was removed from the municipal registry was used as date of censoring. To calculate the risk of incident hypertension and diabetes during the followup, logistic regression analysis was applied and expressed as odds ratio (OR). For logistic regression analyses, data were used from the baseline screening through the last screening that participants attended. HRs and ORs were subsequently also adjusted for covariates using several models. First, we adjusted for age and gender; secondly, we adjusted for age, gender and cardiovascular risk factors (body mass index, cholesterol, serum uric acid, glucose, SBP and smoking).
As sensitivity analysis, all analyses were repeated with albuminuria assessed as albumin-tocreatinine ratio (ACR) measured in the baseline 24-h urine collections. Microalbuminuria was defined as an ACR between 30 and 300 mg/g. In addition, we repeated all analyses with additional adjustment for baseline eGFR, and for diabetes de novo after exclusion of subjects with borderline diabetes mellitus (defined as a fasting glucose between 6.1 and 7.0 mmol/L).
Results
Of the 8356 subjects included in the present analysis 5434 had at baseline no CVD history, hypertension or diabetes, of which 300 met the definition of isolated microalbuminuria (5.2%) ( Table 1) . Of the 2922 subjects with either a CVD history, hypertension or diabetes at baseline, 633 had microalbuminuria (21.7%). Subjects 'without' baseline CVD history, hypertension or diabetes were significantly younger and by definition had a lower cardiovascular risk profile than subjects 'with' baseline CVD history, hypertension or diabetes. In each of these two subgroups, the subjects that had microalbuminuria were older and had a higher cardiovascular risk profile than subjects without microalbuminuria. The subgroup with isolated microalbuminuria had the highest percentage of smokers. Subjects with CVD, hypertension or diabetes at baseline had a lower eGFR when compared with subjects without these risk factors, whatever the degree of albuminuria. However, age was also different in these subgroups, which may influence these findings. When we adjusted for age the difference in eGFR between subjects with and without CVD, hypertension or diabetes at baseline was not significant. Table 2 shows that the incidence rate per 1000 person-years of follow-up in the subgroup with isolated microalbuminuria was 15.3 for CVD and mortality, 28.9 for hypertension and 8.9 for diabetes. The age-and sex-adjusted relative risk of subjects with isolated microalbuminuria to develop the various outcomes under study in comparison to subjects without microalbuminuria and, similarly, no CVD history, hypertension or diabetes at baseline were significantly increased by a factor of 1.54 (incident cardiovascular events and mortality) to 4.20 (incident diabetes mellitus). When additionally adjusting also for cardiovascular risk factors the relative risk of subjects with isolated microalbuminuria to develop the various outcomes under study in comparison to subjects without microalbuminuria and, similarly, no CVD history, hypertension or diabetes at baseline were significantly increased by a factor of 1.37 for incident cardiovascular events and mortality (P=0.05) and 3.00 for incident diabetes mellitus (P<0.001) ( Table 2) , whereas only for incident hypertension was significance lost (in the full adjusted model P=0.16). Likewise, in the subgroup of subjects that did have a CVD history, hypertension or diabetes at baseline presence of microalbuminuria was associated with a higher risk for these outcomes. The relative risk for each of these outcomes associated with presence of isolated microalbuminuria was numerically higher when compared with the relative risk associated with microalbuminuria in the subgroup of subjects that did have CVD, hypertension or diabetes at baseline (Table 2) .
When cardiac (n =585), cerebral (n =171) and peripheral (n =57) events were studied separately, isolated microalbuminuria was positively associated with all three subgroups of events, although these associations did not reach statistical significance because of a loss of power due to the lower number of events for analyses. 48 had the highest risk for cardiovascular events. Subjects with isolated microalbuminuria were also at higher risk for cardiovascular events and mortality compared with the reference group.
When adjusted for age and gender, it appeared that the risk for cardiovascular events and mortality in subjects with isolated microalbuminuria was similar or even slightly stronger than in the subgroup of subjects with a history of CVD, hypertension or diabetes and absence of microalbuminuria ( Figure 1, lower panel) .
Sensitivity analyses
When microalbuminuria was defined as an ACR of 30-300 mg/g instead of as a urinary albumin excretion of 30-300 mg/24h, it appeared that at baseline 212 participants were defined to have isolated microalbuminuria, and that 380 participants had microalbuminuria in the presence of a CVD history, hypertension or diabetes (baseline characteristics represented in Supplementary   Table S1 ). The results in subjects with isolated microalbuminuria according to this definition were in general identical to our primary analyses with in the full-adjusted models a significantly increased risk for incident CV events and mortality (P<0.001) and incident hypertension (P=0.05), whereas the association with incident diabetes lost significance (Supplementary Table S2 ). When we additionally adjusted for baseline eGFR, this did not materially influence the 
Discussion
In the present study, using data of an observational, general population-derived cohort, we showed that isolated microalbuminuria (i.e. microalbuminuria in the absence of a CVD history, hypertension and diabetes) is associated with an increased risk for incident cardiovascular events and mortality, incident hypertension and/or diabetes mellitus.
Chapter 3
Several studies have previously investigated the association between microalbuminuria and risk for cardiovascular events and mortality. Most of these have been summarized in recent meta-analyses (1, 4) . Of note, these studies were performed in cohorts, including only subjects at high risk for CVD (4), or in general population cohorts that included a case mix of low-and high-risk subjects (1). Only Ärnlöv et al. have investigated the value of albuminuria in nonhypertensive, non-diabetic individuals. They concluded that, in these subjects, low levels of albuminuria, well below the current microalbuminuria threshold, predicted the development of CVD (19). As far as we are aware, no study has yet investigated specifically the association of isolated microalbuminuria with incident cardiovascular events and mortality. Our study adds therefore new information to the existing literature.
We defined isolated microalbuminuria as microalbuminuria in the absence of a CVD history, hypertension and diabetes. Of our population, 5.2% met this definition. The incidence rate for CVD and mortality per 1000 person-years of follow-up in this subgroup was 15.3. When compared with subjects without any risk factor (i.e. no microalbuminuria, CVD history, hypertension or diabetes) the age-and sex-adjusted relative risk of subjects with isolated microalbuminuria to reach this end point was 1.54. When also adjusted for cardiovascular risk factors, the HR was 1.37, still significant. Importantly, the adjusted relative risk for this outcome associated with presence of isolated microalbuminuria was numerically equal or even slightly higher when compared with the relative risk associated with microalbuminuria in the subgroup of subjects that did have a history of CVD, hypertension or diabetes at baseline (Table 2 and Figure 1 ), and when compared with subjects with a CVD history, hypertension or diabetes, but without microalbuminuria.
Microalbuminuria is often regarded as a sign of organ damage, reflecting the degree of cardiovascular damage induced by hypertension or diabetes mellitus. Our data show that in 32% [300/(300 + 633)] of microalbuminuric subjects, microalbuminuria was present in the absence of a CVD history, hypertension or diabetes. Interestingly, a limited number of studies showed that microalbuminuria may also precede the development of hypertension (12, 13) or diabetes (10, 20) . In the studies investigating the incidence of de novo hypertension, subjects with baseline (pre)hypertension were excluded, whereas in the studies investigating the incidence of de novo diabetes, this was done for baseline (pre)diabetes. Our study corroborates these findings and extends the presently available knowledge insofar that it shows that microalbuminuria predicts de novo hypertension and/or diabetes mellitus, even when all subjects are excluded that had at baseline either a CVD history or hypertension or diabetes.
Thus, even using these rigid exclusion criteria, the predictive value of microalbuminuria for these outcomes remained present, highlighting the robustness of our findings.
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Although answering the question what causes the increase in glomerular permeability in the subjects with isolated microalbuminuria is hypothetical, and no proof can be derived from the present paper, several options can be considered. First, blood pressure and glucose levels are continuous variables and may lead to damage of the glomerular filtration barrier even when values are below the cut-off values presently defining hypertension and diabetes mellitus, especially in subjects who are susceptible. Furthermore, besides CVD, hypertension and diabetes mellitus, there are other factors that can lead to increased glomerular permeability, for example increased serum uric acid (21) . Finally, there may be a genetic or inborn component (22) .
What may be the consequences of our findings? Our data show that isolated microalbuminuria is associated with an increased risk for cardiovascular events and mortality. As such, preventive treatment may seem warranted. However, it should be kept in mind that the decision to treat subjects with for instance blood pressure-lowering drugs is not only based on increased relative risk, but also on absolute risk. We observed that the incidence rate in subjects with isolated microalbuminuria was 15.3 per 1000 person-years, which translates as a 10-year risk for a cardiovascular events or mortality of 15.3%. This is in the range in which prevailing guidelines advocate to consider starting cardiovascular protective treatment (23) . It may be expected that the event rate in elderly subjects is higher. It could therefore be an option to start such treatment especially in elderly subjects with isolated microalbuminuria. In younger subjects, lifestyle changes could be advised (e.g. stop smoking or losing weight), and they could be monitored without starting treatment until they develop further increases in albuminuria, de novo hypertension or diabetes, or an absolute risk for cardiovascular events and mortality that exceeds the threshold for starting treatment. It should also be kept in mind that, although it seems likely that cardiovascular protective treatment may ameliorate prognosis in subjects with isolated microalbuminuria, evidence to support this assumption is limited (24) and more evidence is needed.
We acknowledge that the present study has limitations. First, some variables under investigation were based on self-report, which may have led to misclassification. In the present study, however, questionnaire data were combined with objective data, retrieved from pharmacy databases (medication use) or quantitatively measured (glucose and blood pressure), making our data as robust as possible. Secondly, in our multivariable models, we also adjusted for cardiovascular risk factors, such as blood pressure and glucose. However, subjects with isolated microalbuminuria had by definition blood pressure and glucose levels that according to prevailing guidelines do not warrant start of blood pressure-or glucose-lowering treatment.
It is therefore questionable whether such adjustment is necessary. Thirdly, the PREVEND Chapter 3 cohort comprises predominantly subjects of Caucasian descent. Whether our data hold true for other populations needs additional study. Finally, in our cohort, only 300 subjects met the definition of isolated microalbuminuria, limiting the power of especially multivariable analyses.
Still most results remained statistical significant.
Besides limitations, our study has also important strengths. This study was performed in a relatively large observational cohort of community-dwelling subjects, in whom extensive information on subject characteristics was available. At baseline, albuminuria and blood pressure were measured on two occasions, and the average value was taken. The population included covers a wide age range. Furthermore, information on adverse health outcomes was collected in an objective manner (measurement of blood pressure and glucose, pharmacy data and record linkage with databases of health authorities) during a relatively long follow-up time.
These prerequisites allow an adequate estimation of the prevalence of, and risk associated with isolated microalbuminuria in the general adult population.
In conclusion, isolated microalbuminuria is associated with an increased risk for cardiovascular events and mortality, as well as for incident hypertension and diabetes mellitus. Isolated microalbuminuria indicates, therefore, a poor prognosis and as such warrants medical attention.
Whether the presence of isolated microalbuminuria should result in medical intervention to prevent these outcomes needs further study, but especially in elderly this may be an option.
Supplementary Table 1 . Baseline characteristics of the study population subdivided according to presence or absence of hypertension, diabetes or cardiovascular disease history, and presence or absence of microalbuminuria. 
